You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Delivered daily
Kiplinger Today
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more delivered daily. Smart money moves start here.
Sent five days a week
Kiplinger A Step Ahead
Get practical help to make better financial decisions in your everyday life, from spending to savings on top deals.
Delivered daily
Kiplinger Closing Bell
Get today's biggest financial and investing headlines delivered to your inbox every day the U.S. stock market is open.
Sent twice a week
Kiplinger Adviser Intel
Financial pros across the country share best practices and fresh tactics to preserve and grow your wealth.
Delivered weekly
Kiplinger Tax Tips
Trim your federal and state tax bills with practical tax-planning and tax-cutting strategies.
Sent twice a week
Kiplinger Retirement Tips
Your twice-a-week guide to planning and enjoying a financially secure and richly rewarding retirement
Sent bimonthly.
Kiplinger Adviser Angle
Insights for advisers, wealth managers and other financial professionals.
Sent twice a week
Kiplinger Investing Weekly
Your twice-a-week roundup of promising stocks, funds, companies and industries you should consider, ones you should avoid, and why.
Sent weekly for six weeks
Kiplinger Invest for Retirement
Your step-by-step six-part series on how to invest for retirement, from devising a successful strategy to exactly which investments to choose.
To a blurry eye, Bausch Lomb's beaten-up share price might look like a buying opportunity. If your vision is clear, it's not.
The stock (symbol BOL) has plummeted 20% since Monday, when the company said it would temporarily stop shipments of its ReNu with MoistureLoc contact lens solution. The reason: fear that the product might be connected with a rare fungal eye infection. The stock market could be overreacting. It did, after all, do just that to Sherwin-Williams in February after a jury found the company liable in a lead-paint case. That stock lost one-fifth of its value in a single day. But it has recovered almost fully as the market reassessed the implications to Sherwin-Williams' businesses and found them less than dire.
However, with Bausch Lomb, savvy investors would be wise to hold off rather than expect a quick bounceback, analysts say. Although there's no evidence that the infections are caused by the firm's product, the uncertainty is great and the full implications unknown.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The Centers for Disease Control and Prevention is investigating several reports of Fusarium keratitis infections. The cause of the infections has yet to be determined, "although evidence thus far remains concerning" for BL, says Suey Wong, an analyst at Robert W. Baird Co. Nearly all of the infected patients so far reviewed by the CDC have said they used ReNu products. How long the investigation will take isn't clear. But in the meantime, the brand name is tainted. Major retail chains are pulling ReNu products from their shelves.
This is a big deal for BL. It generates 23% of its sales from lens-care products, sold under the Bausch Lomb, Boston, ReNu and Sensitive Eyes names. It launched ReNu with MoistureLoc in 2004. Bank of America analyst David Maris says that brand isn't likely to return to the U.S. market, resulting in the loss of $45 million in potential sales this year. He figures BL will lose share of the overall lens care market and that its contact lens sales could be hurt as well. "We think the brand damage on ReNu will be sizable and carry over into the Bausch Lomb overall brand globally," he says. On Wednesday, Maris lowered his 2006 earnings per share estimate from $4.24 to $3.05. He also lowered his 12-month target price for the stock from $49 to $40 and maintains a "sell" rating.
Maris also wonders what the company will say to some questions about its handling of the situation, including why doctors weren't notified sooner and the timeline wasn't explained better to investors. Such worries could add to the long-term problems for the firm, in his view.
BL has more worries than ReNu. Competition among eye-care companies -- including Johnson Johnson, Alcon and others -- is tough. Analysts acknowledge that BL hasn't invested enough in research and development, resulting in a weak product pipeline. Wong, who rates the stock "neutral," points out that a recent accounting scandal at a subsidiary in Brazil caused the company to restate five years of financial results and that accounting at a Korean subsidiary is also under investigation. BL said this week that it would further delay its 10-K filing.
--Lisa Dixon
-
Dow Leads in Mixed Session on Amgen Earnings: Stock Market TodayThe rest of Wall Street struggled as Advanced Micro Devices earnings caused a chip-stock sell-off.
-
How to Watch the 2026 Winter Olympics Without OverpayingHere’s how to stream the 2026 Winter Olympics live, including low-cost viewing options, Peacock access and ways to catch your favorite athletes and events from anywhere.
-
Here’s How to Stream the Super Bowl for LessWe'll show you the least expensive ways to stream football's biggest event.
-
If You'd Put $1,000 Into AMD Stock 20 Years Ago, Here's What You'd Have TodayAdvanced Micro Devices stock is soaring thanks to AI, but as a buy-and-hold bet, it's been a market laggard.
-
If You'd Put $1,000 Into UPS Stock 20 Years Ago, Here's What You'd Have TodayUnited Parcel Service stock has been a massive long-term laggard.
-
How the Stock Market Performed in the First Year of Trump's Second TermSix months after President Donald Trump's inauguration, take a look at how the stock market has performed.
-
If You'd Put $1,000 Into Lowe's Stock 20 Years Ago, Here's What You'd Have TodayLowe's stock has delivered disappointing returns recently, but it's been a great holding for truly patient investors.
-
If You'd Put $1,000 Into 3M Stock 20 Years Ago, Here's What You'd Have TodayMMM stock has been a pit of despair for truly long-term shareholders.
-
If You'd Put $1,000 Into Coca-Cola Stock 20 Years Ago, Here's What You'd Have TodayEven with its reliable dividend growth and generous stock buybacks, Coca-Cola has underperformed the broad market in the long term.
-
If You Put $1,000 into Qualcomm Stock 20 Years Ago, Here's What You Would Have TodayQualcomm stock has been a big disappointment for truly long-term investors.
-
If You'd Put $1,000 Into Home Depot Stock 20 Years Ago, Here's What You'd Have TodayHome Depot stock has been a buy-and-hold banger for truly long-term investors.
